Skip to main content
OpenTrials
Completed

NCT Number: NCT03319472

Using Pleural Effusions to Diagnose Cancer

Pleural effusions (PE) are common conditions that signal either infection or cancer. The investigators aim to develop, validate, and prospectively assess the MAPED score, a clinical score that predicts malignancy at admission. This tool will assist clinicians all over the world to rapidly assess the probability of an effusion being malignant within 4 hours of admission.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Patras University Hospital

Rio, Achaia, 26504, Greece

About this study

Background: Pleural effusions (PE) are common conditions that signal either pleural-disseminated infection or cancer. While these diagnoses bear tremendous importance for patients, they require invasive procurement of pleural tissues and/or cells and time. Simple and rapid diagnostic markers of pleural malignancy at admission that streamline diagnostic and treatment efforts remain unidentified.

Objective: To develop, validate, and prospectively assess markers of malignancy of PE at admission.

Methods: A prospective cohort of patients with PE from different etiologies will be recruited stating on 11.21.2013 and prospectively ending on 11.21.2023. Data will be collected within 4 hours of admission including history, chest X-ray, and blood and pleural fluid (PF) cell counts and basic biochemistry. Pleural fluid and serum will be biobanked for future analyses. Patients will sign informed consent forms. Diagnosis will be confirmed using standard microbiology, cytology, histology, and imaging techniques. Patients undiagnosed within a month will be excluded. Variables will be entered into binary regression and receiver-operator analyses using malignancy as the target to develop the MAPED score, a clinical score that predicts malignancy at admission. MAPED will be retrospectively validated in separate published cohorts from the first therapeutic interventions in malignant effusion (TIME) 1-3 trials from Oxford UK. Data will be censored and analyzed three times, at 40-month intervals since study initiation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pleural effusion
  • Hospital admission
  • No previous pleural procedure
  • Age > 18 years
  • No previous chemoradiotherapy
  • No antibiotic therapy during previous trimester
  • All history, chest X-ray, and pleural and blood cell counts and biochemistry entry data obtained within 4 hours after admission

Exclusion criteria

  • No diagnosis at one month post-admission
  • No informed consent provided
  • Age < 18 years
  • History, chest X-ray, or pleural and blood cell counts and biochemistry entry data obtained later than 4 hours after admission

Treatment and study plan

Primary outcomes

  1. Diagnosis of Malignancy

    Time frame: One month post-admission

    Cytologic or histologic evidence of malignant cells or tissues in the pleural space.

Sponsors and collaborators

Lead sponsor

University of Patras

Other

Registry information

Official study title

Clinical Identification of Malignant Pleural Effusions in the Emergency Department

Acronym: MAPED

Important dates

Study start
2013
Primary completion
2017
Study completion
2018
First posted
Oct 24, 2017
Registry last updated
Dec 10, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.